Newsletter Subscription

Enter Name and Email

NeuroAct Communication - Newsletter - April 2011


Expertise in Neuropharmacology





Spring News

New "Search" function
To facilitate navigation of the NeuroAct Communication web site, a "Search" function is now available at the left-hand side of the screen. This became necessary in view of the increasing volume of information, including descriptions of consulting services, endorsements, publications and news. The site currently totals over 130 pages.


ECNP awards fast-track membership
The European College of Neuropsychopharmacology (ECNP) recently awarded Adrian Newman-Tancredi fast-track membership approval. Adrian had recently given a well-received lecture at the Amsterdam ECNP meeting in August 2010 (watch Webcast), and published data on a novel antidepressant in the society's journal, European Neuropsychopharmacology (read Abstract). Adrian's membership of the ECNP became effective on the 1st January 2011.






NeuroAct Communication is an independent consulting service founded by Adrian Newman-Tancredi Ph.D.,
an experienced pharmaceutical industry professional.

Find out more about Adrian in his Executive Profile

NeuroAct Communication advises lifescience companies and funding agencies on neuropharmacology and central nervous system drug discovery programs.

Find out about our Consulting Services.


Scientific Communication

Research seminar
Adrian gave a seminar on 4 March 2011 to researchers at the CERMEP positron emission tomography (PET) brain imaging centre of the Boulevard Pinel Hospital Complex in Lyon, France.
His presentation, entitled "New mechanisms and novel drugs: how recent discoveries are opening perspectives for targeting serotonergic neurotransmission", focussed on recent concepts of "biased agonism" and "functional selectivity".


Just Published
Comparative pharmacology of antipsychotics possessing combined dopamine D2 and serotonin 5-HT1A receptor properties.
Newman-Tancredi A, Kleven MS.
Psychopharmacology (Berl). 2011 Mar 11. [Epub]

Several recent antipsychotics combine antagonism (or partial agonism) at D2 receptors with agonism at serotonin 5-HT1A receptors. Such drugs include aripiprazole (Abilify®, BMS/Otsuka), Lurasidone (Latuda®, DainipponSumitomo) and cariprazine (PhIII, Forest/Richter). This review discusses such drugs on the basis of systematic pharmacological comparisons and the latest available publications.


To find out how Adrian can assist you in scientific communication contact.